BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
glucose metabolic process
,
Allergy to pollen
,
Embryo
,
Hematopoietic cell
,
rs3825942
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
SAMD9L
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Spleen
Tonsil
Thymus gland
Lymph nodes
Lung
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Identification of sterile a-motif domain-containing 9-like as a potential biomarker in patients with…
New SAMD9L heterozygous mutation leading to myelodysplastic syndrome and acute myeloid leukemia: A c…
Germline SAMD9L truncation variants trigger global translational repression.
Up-regulated SAMD9L modulated by TLR2 and HIF-1α as a promising biomarker in tuberculosis.
SAMD9L autoinflammatory or ataxia pancytopenia disease mutations activate cell-autonomous translatio…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis Wit…
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of …
Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ